Angioimmunoblastic T-cell lymphoma (AITL) is a rare and fast-growing cancer of the immune system, affecting mostly older adults and presenting unique challenges in treatment. Because this disease often progresses quickly and responds unpredictably to therapy, doctors rely on a combination of established chemotherapy regimens and promising new approaches currently being evaluated in clinical trials.

How Treatment Aims to Control This Aggressive Disease

Treatment for angioimmunoblastic T-cell lymphoma focuses on several important goals. The primary aim is to control the cancer’s growth and bring the disease into remission, which means eliminating all detectable signs of lymphoma from the body. Because AITL grows quickly and often spreads to multiple parts of the body by the time it is diagnosed, treatment must be started promptly to prevent further complications.^[1]

Another critical treatment goal involves managing the immune system problems that AITL causes. This lymphoma creates abnormal responses in the body’s defense system, leading to conditions where the immune system mistakenly attacks healthy tissues. Doctors work to control these reactions while fighting the cancer itself. Treatment also aims to reduce symptoms that significantly affect daily life, such as fever, night sweats, skin rashes, and severe fatigue.^[2]

The approach to treating AITL depends heavily on individual patient characteristics. Age, overall health status, and the presence of other medical conditions all influence which treatments doctors recommend. The stage of disease matters too, although most patients are diagnosed when the lymphoma has already spread to multiple areas of the body. The medical team considers whether a patient is strong enough to tolerate intensive treatments, including potential stem cell transplantation.^[3]

Treatment planning involves both standard therapies approved by medical organizations worldwide and participation in research studies testing newer drugs. Because AITL remains difficult to cure with conventional approaches, clinical trials offer access to innovative treatments that might provide better outcomes. These trials represent an important option, particularly for patients who experience disease relapse after initial therapy.^[8]

Standard Treatment Approaches for AITL

The foundation of initial treatment for angioimmunoblastic T-cell lymphoma consists of combination chemotherapy regimens. The most commonly used protocol is called CHOP, which stands for four drugs used together: cyclophosphamide, doxorubicin (also known as hydroxydaunorubicin), vincristine (Oncovin), and prednisone. This combination has been used for many years to treat various types of lymphoma and remains the standard first approach for AITL.^[3]

Each drug in the CHOP regimen works in a different way to attack cancer cells. Cyclophosphamide damages the DNA inside lymphoma cells, preventing them from dividing and multiplying. Doxorubicin interferes with enzymes that cancer cells need to copy their genetic material. Vincristine stops cells from dividing by disrupting their internal structure. Prednisone, a steroid medication, has multiple effects including reducing inflammation and causing cancer cells to die.^[9]

Patients receive CHOP chemotherapy in cycles, typically every three weeks. Each cycle involves receiving the medications through an intravenous line, usually in a single day, followed by a recovery period at home. Most treatment plans include six to eight cycles, meaning the entire course of chemotherapy lasts approximately four to six months. During this time, patients visit the treatment center regularly for blood tests to monitor how their body is responding.^[5]

A newer modification of CHOP called BV+CHP is also used in some centers. This regimen replaces vincristine with brentuximab vedotin (BV), a targeted therapy that may be more effective and cause different side effects. The decision about which regimen to use depends on individual patient factors and what the treatment center offers.^[2]

Chemotherapy causes side effects because it affects not only cancer cells but also healthy cells that divide rapidly. Common side effects include nausea and vomiting, which can usually be controlled with anti-nausea medications. Hair loss occurs in most patients receiving CHOP, though hair typically grows back after treatment ends. Fatigue is nearly universal and may persist throughout the treatment course.^[18]

More serious side effects require close monitoring. Chemotherapy temporarily reduces the production of blood cells in the bone marrow, leading to low white blood cell counts that increase infection risk, low red blood cell counts causing anemia, and low platelet counts that can cause bleeding problems. Patients must watch for signs of infection such as fever, which requires immediate medical attention. Some patients receive growth factor injections to stimulate white blood cell production between chemotherapy cycles.^[8]

Heart problems can occur with doxorubicin, particularly in patients with pre-existing heart conditions or those who have received high cumulative doses. Doctors monitor heart function with tests such as echocardiograms before and during treatment. Vincristine can damage nerves, causing numbness, tingling, or pain in the hands and feet, a condition called peripheral neuropathy. These symptoms may improve after treatment stops but can sometimes persist.^[18]

For patients who achieve a good response to initial chemotherapy, doctors may recommend stem cell transplantation as a way to reduce the risk of the lymphoma returning. An autologous stem cell transplant uses the patient’s own stem cells, which are collected from the blood before the patient receives very high doses of chemotherapy. After this intensive treatment destroys the remaining lymphoma cells along with the bone marrow, the stored stem cells are returned to the patient’s body to rebuild the blood-forming system.^[8]

However, the benefit of autologous transplantation in AITL remains somewhat controversial. Some studies suggest it provides only temporary control of the disease, as AITL frequently relapses even after this aggressive approach. For this reason, not all experts recommend autologous transplant, and decisions must be individualized based on the patient’s age, overall health, and response to initial therapy.^[5]

When AITL returns after initial treatment or does not respond adequately, allogeneic stem cell transplantation offers the best chance for long-term remission. This procedure uses stem cells from a healthy donor—either a family member with matching tissue types or an unrelated volunteer donor found through international registries. The donor’s immune cells can recognize and attack any remaining lymphoma cells, an effect called graft-versus-lymphoma. However, allogeneic transplant carries significant risks, including potentially life-threatening complications from graft-versus-host disease, where the donor immune cells attack the patient’s normal tissues.^[8]

Innovative Therapies Being Tested in Clinical Trials

Research into new treatments for AITL has expanded significantly in recent years as scientists have learned more about the genetic changes and biological processes driving this disease. Clinical trials are evaluating multiple novel approaches that target specific features of AITL cells, potentially offering more effective and less toxic alternatives to conventional chemotherapy.^[4]

One promising category of experimental drugs includes epigenetic modifiers, which work by changing how genes are turned on or off in cancer cells without altering the DNA sequence itself. Scientists have discovered that AITL cells frequently carry mutations in genes called TET2 and DNMT3A, which normally regulate chemical modifications to DNA. These mutations lead to abnormal gene activity patterns that promote cancer growth.^[4]

Histone deacetylase (HDAC) inhibitors represent one type of epigenetic modifier showing particular promise in AITL. These drugs block enzymes that remove chemical tags from histone proteins, which are the spools around which DNA wraps inside cells. By preventing this removal, HDAC inhibitors change gene expression patterns in ways that can stop cancer cells from dividing or cause them to die. Several HDAC inhibitors have been tested in clinical trials for relapsed AITL, showing preferential activity in this specific lymphoma subtype compared to other peripheral T-cell lymphomas.^[8]

Panobinostat (brand name Farydak) is one HDAC inhibitor that has been evaluated in small clinical trials for AITL. Early results showed that some patients achieved responses, with tumors shrinking and symptoms improving. The drug is given as a pill taken on specific days each week. Common side effects include fatigue, diarrhea, nausea, and decreases in blood cell counts. Researchers continue studying panobinostat both alone and in combination with other drugs to determine the best way to use it.^[9]

Another class of epigenetic drugs called hypomethylating agents also shows activity against AITL. These medications work by blocking DNMT enzymes, the same enzymes that are mutated in many AITL patients. By inhibiting these enzymes throughout the body, hypomethylating agents restore more normal patterns of gene activity. Drugs in this category are given by injection and were originally developed for treating certain blood cancers related to bone marrow failure.^[8]

Brentuximab vedotin (Adcetris) represents a different type of targeted therapy that has demonstrated effectiveness in some AITL patients. This drug is an antibody-drug conjugate, meaning it consists of an antibody attached to a powerful chemotherapy molecule. The antibody portion recognizes a protein called CD30 that appears on the surface of some AITL cells. When brentuximab vedotin attaches to CD30, the lymphoma cell takes the drug inside, where the chemotherapy is released and kills the cell from within.^[9]

Clinical trials of brentuximab vedotin in relapsed AITL have shown response rates ranging from 30% to 50% of patients. The drug is given through intravenous infusion, typically once every three weeks. Side effects include peripheral neuropathy (numbness and tingling), fatigue, nausea, and low blood cell counts. Because not all AITL tumors have high levels of CD30 on their surface, doctors may test biopsy samples to predict which patients are most likely to benefit from this therapy.^[18]

Phosphoinositide-3-kinase (PI3K) inhibitors are another category of targeted drugs showing promise in AITL clinical trials. PI3K is a signaling molecule inside cells that helps control growth, survival, and movement. AITL cells often have overactive PI3K signaling, particularly through an enzyme subtype called PI3K-delta. Drugs that block this enzyme can interfere with survival signals that lymphoma cells depend on.^[18]

Several PI3K inhibitors have entered clinical testing for AITL and other T-cell lymphomas. These medications are taken as pills, usually twice daily. Common side effects include diarrhea, skin rashes, and increased susceptibility to infections. More serious complications can include inflammation of the lungs or liver, requiring careful monitoring. Researchers are working to identify which AITL patients will respond best to PI3K inhibitors and how to manage side effects effectively.^[18]

Lenalidomide (Revlimid) is an immunomodulatory drug that has shown activity against AITL in early clinical trials. This medication works through multiple mechanisms, including direct effects on cancer cells, stimulation of immune cells to attack lymphoma, and interference with blood vessel formation that tumors need to grow. Lenalidomide is taken as a daily pill in cycles of several weeks on treatment followed by a week off. Side effects can include low blood cell counts, fatigue, and increased risk of blood clots in some patients.^[9]

An exciting frontier in AITL treatment involves CAR T-cell therapy, a type of immunotherapy where a patient’s own immune cells are genetically modified to recognize and attack cancer cells. Recent research has explored the possibility of creating CAR T-cells that target CD4, a protein found on the surface of AITL cells. Because CD4 is also present on normal helper T-cells, special strategies are needed to prevent the CAR T-cells from destroying each other—a problem called fratricide.^[12]

Scientists have developed an innovative approach to overcome this challenge by engineering the CAR therapy to enter only CD8 T-cells (a different type of immune cell that lacks CD4), which can then attack the CD4-positive AITL cells without self-destruction. In preclinical studies using a mouse model that closely mimics human AITL, this strategy successfully eliminated malignant cells and extended survival. Even more remarkably, researchers demonstrated that CAR T-cells could be generated directly inside the body (in vivo) rather than requiring cells to be removed, modified in a laboratory, and returned to the patient—a process that is expensive and time-consuming.^[12]

Clinical trials for AITL are conducted at specialized cancer centers in the United States, Europe, and other regions worldwide. Patient eligibility for trials depends on multiple factors including the stage and characteristics of the disease, previous treatments received, overall health status, and specific requirements of each study protocol. Some trials enroll only patients whose lymphoma has relapsed or not responded to standard therapy, while others test new approaches as first-line treatment.^[4]

Researchers are also investigating biomarkers that might predict which patients will respond to specific targeted therapies. For example, studies are examining whether the presence of particular gene mutations (such as RHOA or IDH2 mutations) correlates with response to certain drugs. Understanding these relationships could eventually allow doctors to personalize treatment selection based on the genetic profile of each patient’s lymphoma, moving toward more individualized and effective therapy.^[4]

Ongoing research continues to identify new molecular targets specific to AITL biology. Scientists have learned that AITL cells originate from a special type of helper T-cell called a follicular helper T-cell (Tfh), which normally assists B-cells in producing antibodies. These Tfh cells release various chemical signals called cytokines and chemokines that create the complex tumor environment characteristic of AITL. Drugs that interfere with these signaling pathways or block the interactions between malignant Tfh cells and their surrounding environment represent future therapeutic possibilities.^[4]

Most Common Treatment Methods

• Combination Chemotherapy
  • CHOP regimen (cyclophosphamide, doxorubicin, vincristine, prednisone) given every three weeks for six to eight cycles as standard first-line treatment^[3]
  • BV+CHP regimen replacing vincristine with brentuximab vedotin as an alternative initial approach^[2]
  • Pre-treatment with steroids (prednisone 100 mg daily) for symptom control before starting chemotherapy^[8]
• Stem Cell Transplantation
  • Autologous stem cell transplant using patient’s own cells after high-dose chemotherapy, with controversial benefit in AITL^[5]
  • Allogeneic stem cell transplant using donor cells offering best chance for long-term remission in relapsed disease^[8]
• Targeted Therapies in Clinical Trials
  • Epigenetic modifiers including histone deacetylase inhibitors like panobinostat (Farydak)^[9]
  • Hypomethylating agents that block DNMT enzymes^[8]
  • Brentuximab vedotin (Adcetris), an antibody-drug conjugate targeting CD30 protein on AITL cells^[9]
  • Phosphoinositide-3-kinase (PI3K) inhibitors blocking overactive signaling pathways^[18]
  • Lenalidomide (Revlimid), an immunomodulatory drug with multiple anticancer mechanisms^[9]
• Immunotherapy Approaches
  • CAR T-cell therapy using genetically modified immune cells to target CD4-positive AITL cells, currently in preclinical development^[12]
  • In vivo CAR T-cell generation allowing immune modification directly inside the body^[12]